Skip to main content
. 2014 Jan 5;5(1):58–68. doi: 10.7150/jca.7047

Table 3.

Current standards for using tumor markers in the metastatic setting

CA 15-3
CA 27.29
NCCN: Optional
ASCO: For monitoring patients with metastatic disease during therapy in combination with diagnostic imaging, history, and exam.
CEA NCCN: Optional
ASCO: For monitoring patients with metastatic disease during active therapy in combination with diagnostic imaging, history, and exam.

Adapted from NCCN Guidelines 3.2013 and ASCO Tumor Marker Guidelines (2007).